Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 23.26
- Piotroski Score 2.00
- Grade Hold
- Symbol (SGEN)
- Company Seagen Inc.
- Price $228.74
- Changes Percentage (-0.07%)
- Change -$0.16
- Day Low $228.74
- Day High $228.96
- Year High $228.96
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $170.00
- High Stock Price Target $222.00
- Low Stock Price Target $120.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$4.00
- Trailing P/E Ratio -57.185
- Forward P/E Ratio -57.185
- P/E Growth -57.185
- Net Income $-610,308,000
Income Statement
Quarterly
Annual
Latest News of SGEN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Controversial Alberta legislation the focus of Transgender Day of Remembrance vigils - Calgary | Globalnews.ca
Events on Transgender Day of Remembrance in Alberta highlighted concerns over proposed legislation impacting the transgender community. Premier Danielle Smith defends the bills for child safety, while...
By Global News | 1 day ago -
SJSU volleyball team with transgender player will be named conference champion if tournament opponents forfeit
San Jose State University's women's volleyball team faces controversy over a transgender athlete, Blaire Fleming. A lawsuit is filed, and the team is uncertain about the upcoming conference tournament...
By Fox News | 1 day ago -
Harris Loss Has Democrats Fighting Over How to Talk About Transgender Rights
In the lead-up to the election, Kamala Harris's campaign faced challenges with Trump's attacks on her transgender rights support, failing to effectively counter them....
By The New York Times | 1 day ago
